Extractables and Leachables (E&L)
In the pharmaceutical industry, the safety and quality of medicines are of paramount importance. Extractables and leachables (E&L) are a key aspect that can influence the purity and safety of medicinal products. These chemical impurities pose a challenge for drug manufacturers, as they can jeopardize both the stability of the drug and the safety of patients.
- Extractables:
Extractables are chemical substances that are released from materials such as plastics, elastomers or coatings under certain conditions, e.g. at elevated temperatures, high pressure or the use of solvents. These substances can be identified through targeted laboratory tests in which extreme conditions are simulated.
- Leachables:
Leachables are substances that can actually migrate into the product during storage or use of a medicinal product and thus reach the patient. They are often caused by the interaction between packaging materials or delivery systems and the drug itself.
Examples of materials that can release extractables and leachables are
- Primary packaging (e.g. vials, syringes, pouches, rubber stoppers)
- Infusion sets and tubing systems
- Sealing materials and coatings
- Process materials, such as filtration systems or tubing
The main cause of extractables and leachables is the use of plastics, elastomers and other synthetic materials that are in direct contact with the drug.
Common sources and causes:
1. Material composition:
Plastics and elastomers contain additives such as plasticizers, stabilizers or antioxidants that can migrate into the drug.
2. Interactions:
Chemical interactions between the drug and the packaging materials can promote the release of substances.
3. Storage conditions:
Factors such as temperature, humidity or storage time influence the release of extractables and the migration of leachables.
4. Manufacturing processes:
Process materials such as tubing or filtration membranes can also release extractables that later appear as leachables in the final product.
The risks posed by extractables and leachables are complex and affect both drug safety and regulatory requirements:
Health risks for patients
- Toxicity: Some leachables can cause toxic effects, especially in sensitive patient groups such as children, pregnant women or chronically ill patients.
- Allergic reactions: Substances such as latex components or certain additives can trigger allergic reactions.
- Cancer risk: Some leachables, such as nitrosamines or polycyclic aromatic hydrocarbons (PAHs), have potentially carcinogenic properties.
Risks for product stability
- Interactions with the drug: Leachables can react chemically with the drug, reducing its efficacy or forming degradation products.
- Particle contamination: Extractables can enter the medicinal product as particles and impair its quality.
Regulatory and legal risks
- Regulatory requirements: Failure to comply with E&L control requirements can lead to delays in the approval of a product.
- Recalls: Identification of undesirable leachables in the product can lead to recalls and reputational damage.
- Liability risks: Health risks from leachables can result in legal consequences and financial losses.
Regulatory authorities such as the FDA (USA), the EMA (Europe) and the ICH (International Council for Harmonization) have developed specific guidelines for the evaluation of extractables and leachables.
Important requirements:
- Risk assessment: Companies must conduct a detailed risk assessment for all materials that come into contact with the drug product.
- Analytical studies: Test procedures for the identification and quantification of extractables and leachables are mandatory.
- Validation: Analyses must be performed using validated methods that are reliable and reproducible.
- Long-term studies: Storage studies are required to evaluate potential leachables throughout the shelf life of a product.
Minimizing extractables and leachables is crucial for the quality and safety of medicines. Pharmaceutical companies use various strategies to reduce the risks:
Material selection and testing
- Selecting materials that are specifically designed for pharmaceutical applications and have low E&L release.
- Carrying out comprehensive tests to identify potential extractables in early development phases.
Optimize manufacturing processes
- Use of inert equipment and process materials that do not release undesirable substances.
- Regular inspection and cleaning of production facilities.
Analytical monitoring
- Implementation of modern analytical methods such as HPLC, GC-MS or LC-MS to identify and quantify extractables and leachables.
- Conducting simulation studies to evaluate possible leachable release scenarios.
Collaboration with suppliers
- Working closely with packaging and material manufacturers to better understand the E&L properties of the materials used.
Extractables and leachables pose a significant challenge for the pharmaceutical industry as they can jeopardize the safety, efficacy and quality of drugs. Comprehensive analysis, careful material selection and compliance with regulatory requirements are crucial to minimize the risks. By using modern analytics and innovative materials, pharmaceutical companies can increase confidence in their products while meeting the growing demands of regulatory authorities. Ultimately, careful E&L management strategies play a key role in ensuring patient health and safety.
Find out more?
Would you like to find out more about our product range or do you have any questions? Do you need an individual offer or information on ordering, delivery and payment conditions? Contact us us by phone, email or live chat.